November 30th 2023
Here are some updates from the world of psychiatry throughout the month of November.
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Visualizing the Role of Antipsychotics in the Management of Schizophrenia: What is the Role of TAAR1?
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Antipsychotic Polypharmacy and Risk of Metabolic Disorders in Schizophrenia
October 9th 2023What is the risk of diabetes, hypertension, or hyperlipidemia with antipsychotic polypharmacy in patients with schizophrenia? Researchers investigated these associations in a population-based prospective cohort study.
Read More
NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia
September 28th 2023The treatment, if approved, “will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”
Read More